Search Results 191-200 of 13511 for Relaxin-2

  1. Neurosurgery - Clinical trials

    ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...

  2. Selective serotonin reuptake inhibitors (SSRIs) - Mayo Clinic

    Serotonin syndrome most often occurs when two medicines that raise the level of serotonin are combined. These include, for example, other antidepressants ...

  3. Neurology - Clinical trials - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  4. ... 2 mL oral solution",122.46 636000003,59365512801,copper 380 square mm ... 2(PF) 10 mcg/0.5 mL (final) IM solution,178.27 636000003,58160095901 ...

  5. Publications - Justin T. Brady, M.D. - Mayo Clinic

    Trends Cancer Res Chemother. 2018; 1(2):1-5. Antunes J, Viswanath S, Brady JT, Crawshaw B, Ros P, Steele S, ...

  6. Neurology - Clinical trials

    ... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...

  7. Senolytics reduce COVID-19 symptoms in preclinical studies - Mayo Clinic News Network

    The researchers also found that older mice infected with viruses, including a coronavirus related to SARS-CoV-2 using a model developed at University of ...

  8. Neurosurgery - Clinical trials

    ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...

  9. Neurology - Clinical trials

    ... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...

  10. Neurology - Clinical trials - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...